February 7, 2014
A New Tide Approaches
Simeprevir and sofosbuvir both represent a further step in the evolution of more effective, less-toxic HCV treatment options. But they, too, are just the beginning. Numerous direct-acting antiretrovirals are currently moving through the latter stage of the development pipeline, suggesting that the treatment landscape by early 2015 may look as different from the present as the present does from just a few years earlier.
For the notoriously hard-to-treat HCV genotype 1 in particular, Cox states: "It's hard to predict, but right now in advanced testing, there are some combinations that are inteferon-sparing" yet have very high sustained virologic response rates -- and may not even require the use of ribavirin.
Myles Helfand is the editorial director of TheBody.com and TheBodyPRO.com.
Follow Myles on Twitter: @MylesatTheBody.
|What Does 2015 Hold in Store for HIV Research?|
|Antiretroviral Neurotoxicity May Cause Cognitive Problems|
|Test for HIV, Hepatitis C and Hepatitis B Approved by FDA|
|The Cynical Connectedness of Gilead's Hepatitis C Pricing and Anti-Diversion Policies|
|HIV-Positive Men Taking Erectile Dysfunction Drugs More Likely to Take Sexual Risks and Have Syphilis|
|Why HIV Vaccines May Be Failing|